Plasma and memory B-cell kinetics in infants following a primary schedule of CRM197-conjugated serogroup C meningococcal polysaccharide vaccine (vol 127, pg 134, 2009)

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM197-conjugated serogroup C meningococcal polysaccharide vaccine (vol 127, pg 134, 2009)

Bibliographic Details
Main Authors:	Kelly, D, Snape, MD, Perrett, K, Clutterbuck, E, Lewis, S, Rohner, G, Jones, M, Yu, L, Pollard, A
Format:	Journal article
Published:	2011

Similar Items

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
by: Kelly, D, et al.
Published: (2009)

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
by: Kelly, D, et al.
Published: (2006)

Meningococcal polysaccharide-protein conjugate vaccines (vol 5, pg 21, 2005)
by: Snape, MD, et al.
Published: (2005)

Erratum: CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells (Blood (2006) 108 (2642-2647))
by: Kelly, et al.
Published: (2007)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
by: Blanchard-Rohner, G, et al.
Published: (2012)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
by: Blanchard-Rohner, G, et al.
Published: (2012)

Meningococcal polysaccharide-protein conjugate vaccines.
by: Snape, MD, et al.
Published: (2005)

Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.
by: Ramasamy, M, et al.
Published: (2014)

A randomised study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide - CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase
by: Riddell, A, et al.
Published: (2007)

A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase.
by: Riddell, A, et al.
Published: (2007)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
by: Snape, MD, et al.
Published: (2006)

The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM197 conjugate vaccine
by: Clutterbuck, E, et al.
Published: (2006)

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
by: Snape, MD, et al.
Published: (2005)

High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.
by: O'Connor, D, et al.
Published: (2017)

B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
by: Perrett, K, et al.
Published: (2012)

Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers
by: Miguel Tregnaghi, et al.
Published: (2014-09-01)

The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age
by: Blanchard-Rohner, G, et al.
Published: (2013)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
by: Khatami, A, et al.
Published: (2011)

Erratum: Meningococcal polysaccharide-protein conjugate vaccines (Lancet Infective Diseases (2005) 5 (21-30)
by: Snape, MD, et al.
Published: (2005)

Impact of serogroup A meningococcal conjugate vaccine for Africa
by: James M. Stuart
Published: (2018-05-01)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine.
by: O'Connor, D, et al.
Published: (2014)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
by: O'Connor, D, et al.
Published: (2014)

The epidemiology of meningococcal disease and the impact of vaccines (vol 9, pg 285, 2010)
by: Khatami, A, et al.
Published: (2011)

O:2-CRM(197) conjugates against Salmonella Paratyphi A.
by: Francesca Micoli, et al.
Published: (2012-01-01)

Will booster doses be required for serogroup B meningococcal vaccine?
by: McQuaid, F, et al.
Published: (2014)

Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine
by: Micoli, F, et al.
Published: (2020)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
by: Snape, MD, et al.
Published: (2009)

Serogroup B meningococcal vaccines-an unfinished story.
by: Sadarangani, M, et al.
Published: (2010)

The zeta function of sl(2)(Z) (vol 12, pg 197, 2000)
by: du Sautoy, M
Published: (2000)

Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.
by: Moore, C, et al.
Published: (2012)

Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.
by: Maiden, M, et al.
Published: (2008)

Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: A community study
by: Daugla, D, et al.
Published: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
by: de Whalley, P, et al.
Published: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
by: De Whalley, P, et al.
Published: (2013)

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine
by: Pavitra Keshavan, et al.
Published: (2018-10-01)

The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response (vol 180, pg 2165, 2008)
by: Rohner, BG, et al.
Published: (2011)

Meningococcal disease serogroup C
by: Cuevas IE, et al.
Published: (2012-03-01)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
by: Pollard, A, et al.
Published: (2013)

The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.
by: Sadarangani, M, et al.
Published: (2014)

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
by: Pace, D, et al.
Published: (2007)